ArticleCureus2025
Adoption and Prescribing Practices of Sodium-Glucose Transport Protein-2 (SGLT-2) Inhibitors and Glucagon-Like Peptide-1 (GLP-1) Agonists in Cardiology: A Cross-Sectional Study in Saudi Arabia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeart failure (HF) and cardiometabolic diseases are a significant global health burden, often coexisting in patients, leading to high morbidity and mortality. The management of these conditions is challenging, and new therapeutic approaches are needed. Sodium-glucose transport protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1)agonists have emerged as promising treatments, demonstrating efficacy in managing both cardiovascular and metabolic outcomes. This study aimed to explore the familiarity, prescribing practices, perceptions, and barriers to the use of SGLT-2 inhibitors and GLP-1 agonists in cardiology practice in Saudi Arabia.
methodsA cross-sectional, survey-based study was conducted with cardiology professionals across Saudi Arabia. Participants were invited through convenience sampling from academic and community hospitals, private practices, and multi-specialty clinics. The self-administered online survey assessed demographic characteristics, familiarity with SGLT-2 inhibitors and GLP-1 agonists, prescribing practices, perceived efficacy and safety concerns, barriers to adoption, and support for increased use. Descriptive statistics and logistic regression analysis were used to evaluate the data.
resultsA total of 250 cardiology professionals participated, with 46% (n=115) specializing in heart failure, 30.4% (n=76) in general cardiology, 16.4% (n=41) in interventional cardiology, 4.8% (n=12) in electrophysiology, and 2.4% (n=6) in other cardiology specialties. Regarding familiarity with SGLT-2 inhibitors, 28% (n=70) were very familiar, 46.8% (n=117) were somewhat familiar, and 14.4% (n=36) were not familiar at all. For GLP-1 agonists, 25.6% (n=64) were very familiar, 42% (n=105) were somewhat familiar, and 20.8% (n=52) were not familiar. Prescription practices showed that 10.8% (n=27) of participants always prescribed SGLT-2 inhibitors for heart failure, and 8.8% (n=22) always prescribed GLP-1 agonists for cardiometabolic diseases. Factors influencing prescription practices included the patient's clinical condition (57.6%, n=144), clinical guidelines (51.6%, n=129), and recent clinical trial data (39.6%, n=99). The primary barriers to adoption included high cost or insurance issues (40.8%, n=102) and concerns about side effects (36.4%, n=91).
conclusionsDespite the proven efficacy of SGLT-2 inhibitors and GLP-1 agonists, their adoption in cardiology is limited by familiarity gaps, cost concerns, and safety issues. Enhanced education, better access to guidelines, and addressing cost barriers are crucial steps to improve the adoption of these medications in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.